Leadership

Kevin A. Lobo
Chairman and Chief Executive Officer

Glenn S. Boehnlein
Vice President, Chief Financial Officer

Yin C. Becker
Vice President, Communications, Public Affairs and Corporate Marketing

Michael D. Hutchinson
Vice President, Chief Legal Officer

Viju S. Menon
Group President, Global Quality and Operations

J. Andrew Pierce
Group President, MedSurg

Bijoy S. N. Sagar
Vice President, Chief Digital Technology Officer

M. Kathryn Fink
Vice President, Chief Human Resources Officer

Spencer S. Stiles
Group President, Neurotechnology, Instruments and Spine

Katherine A. Owen
Vice President, Strategy and Investor Relations

Timothy J. Scannell
President and Chief Operating Officer

Division Presidents

Businesses

Xavier M. C. Berling
Trauma & Extremities

Dylan B. Crotty
Instruments

Brent W. Ladd
Endoscopy

Eric D. Major
Spine

Mark H. Paul
Neurovascular

Bradford L. Saar
Medical

Stuart F. Simpson
Joint Replacement

Brian J. White
Sustainability Solutions

Regions

Maurice Ben-Mayor
South Pacific

Laurence F. I. Hipkin
Eastern Europe, Middle East, Africa

Scott A. MacNair
Canada

Graham A. McLean
Asia Pacific

Hiroyuki Saeki
Japan

Fabrizio Signorin
Latin America

Stuart A. J. Silk
Europe, Middle East, Africa, Latin America, Canada

Other Officers

Dean H. Bergy
VP, Corporate Secretary

William E. Berry, Jr.
VP, Corporate Controller

Jeanne M. Blondia
VP, Finance and Treasurer

Irene B. Corbe
VP, Internal Audit

William J. Cymbaluk
VP, Corporate Regulatory Affairs and Quality Assurance

David G. Furgason
VP, Tax

Bronwen R. Taylor
VP, Compliance and Risk Management

Independent registered public accounting firm

Ernst & Young LLP
Grand Rapids, Michigan

Transfer agent and registrar

American Stock Transfer & Trust Company, LLC
New York, New York

Shareholders needing information regarding their certificates or dividends should contact:

American Stock Transfer & Trust Company, LLC
Operations Center
6201 15th Avenue
New York, New York 11219
800 937 5449
info@amstock.com

Investor contact

Katherine A. Owen
Vice President, Strategy and Investor Relations

Media contact

Yin C. Becker
Vice President, Communications,
Public Affairs and Corporate Marketing

Business development contact

Bryant S. Zanko
Vice President, Business Development

Annual meeting

The Annual Meeting of Shareholders of Stryker Corporation will be held at the Radisson Plaza Hotel at the Kalamazoo Center in Kalamazoo, Michigan, on Wednesday, May 1, 2019, at 2:00 p.m. ET.

Stock listing

The company’s common stock is traded on the New York Stock Exchange under the symbol SYK.

Form 10-K

The company files an Annual Report on Form 10-K with the Securities and Exchange Commission. Shareholders may view the 2018 report at www.stryker.com or www.sec.gov.

Our Annual Review contains many of the valuable trademarks owned and/or used by Stryker and our subsidiaries and affiliates in the U.S. and internationally to distinguish products and services of outstanding quality. All other trademarks featured herein are the property of their respective owners.

The products referenced within this review may not all be approved or cleared for sale, distribution or use in the United States.

Forward-looking statements

This Annual Review contains information that includes or is based on forward-looking statements within the meaning of the federal securities laws that are subject to various risks and uncertainties that could cause our actual results to differ materially from those expressed or implied in such statements. Such factors include, but are not limited to: weakening of economic conditions that could adversely affect the level of demand for our products; pricing pressures generally, including cost-containment measures that could adversely affect the price of or demand for our products; changes in foreign exchange markets; legislative and regulatory actions; unanticipated issues arising in connection with clinical studies and otherwise that affect U.S. Food and Drug Administration approval of new products; potential supply disruptions; changes in reimbursement levels from third-party payors; a significant increase in product liability claims; the ultimate total cost with respect to the Rejuvenate recall and other recall-related matters; the impact of investigative and legal proceedings and compliance risks; resolution of tax audits; the impact of the federal legislation to reform the United States healthcare system; costs to comply with medical device regulations; changes in financial markets; changes in the competitive environment; our ability to integrate acquisitions; and our ability to realize anticipated cost savings. Additional information concerning these and other factors is contained in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.